IGM Biosciences
Biotechnology Research • 
Mountain View, California, United States • 51-100 Employees
Company overview
| Headquarters | 325 E Middlefield Rd, Mountain View, California 94043, US |
| Phone number | +16509657873 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Antibody, Autoimmunity, Inflamation, Bispecific |
| Founded | 2010 |
| Employees | 51-100 |
| Socials |
Key Contacts at IGM Biosciences
William Strohl
Member, Board Of Directors
Peter Ojany
Senior Director Of Financial Planning And Analysis
Martin Casillas
Senior Director Financial Planning Analysis
Avneesh Saini
Director, Downstream Process Development
Jake Williams
Executive Director Business Development
Tammy Hill
Director, Regulatory Operations
Katherine Eaton
Sr. Director, Clinical Operations
Saloni Bhardwaj Khurana
Senior Director, Upstream Development
Merle Elloso
Senior Director, Autoimmunity & Inflammation Research
Devinder Ubhi
Director
IGM Biosciences Email Formats
IGM Biosciences uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@igmbio.com), used 43.8% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@igmbio.com | 43.8% |
{first name}{last name} | johndoe@igmbio.com | 43.8% |
{first name} | john@igmbio.com | 12.5% |
About IGM Biosciences
About IGM Biosciences, Inc. IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites, compared to conventional IgG antibodies with only 2 binding sites. We have created unique IgM antibodies with high selectivity, affinity, and avidity that may redefine what is possible for therapeutic antibody medicines. We are committed to exploring how the unique structure and binding properties of the IGM antibody can improve outcomes for patients with these serious conditions. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology, immunology, and inflammation targets. For more information, please visit www.igmbio.com. Imvotamab in Autoimmune and Inflammatory Diseases Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. We believe that Imvotamab, with its 10 binding units for CD20, may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. Our preclinical studies suggest that Imvotamab may offer the potential for deeper depletion of B cells, including those in low CD20 expressing cells, than currently approved antibody therapies. We are evaluating Imvotamab in Phase 1b clinical trials of Imvotamab in severe systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and idiopathic inflammatory myopathies (myositis).
IGM Biosciences revenue & valuation
| Annual revenue | $145,100,000 |
| Revenue per employee | $1,594,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $464,200,000 |
| Total funding | $107,300,000 |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
IGM Biosciences has 43 employees across 9 departments.
Departments
Number of employees
IGM Biosciences Tech Stack
Discover the technologies and tools that power IGM Biosciences's digital infrastructure, from frameworks to analytics platforms.
Security
Video players
Maps
JavaScript libraries
CDN
JavaScript libraries
Miscellaneous
Programming languages
Blogs
SEO
Analytics
United Kingdom
Pakistan
Spain
Italy
Cambodia
IrelandFrequently asked questions
4.8
40,000 users
